11/12/04:
New York Attorney General Eliot Spitzer Takes Aim At Universal Life Resources
SUSIE GHARIB: New York Attorney General Eliot Spitzer upped the
ante today in his investigation of the insurance industry. Spitzer is
suing a second big insurance company, Universal Life Resources, saying its
business practices raised premiums for employees of some of the nation`s
largest companies. Spitzer says Universal Life got millions of dollars in
payments for steering customers to insurers including Metlife, Prudential,
and Unum Provident. The suit alleges those companies had undisclosed deals
with Universal, including service charges that were far above market rate.
Spitzer claims those deals meant four million employees of companies
including Intel, Eastman Kodak, Marriott, UPS and Dell paid higher
insurance premiums than they should have. We tried repeatedly to reach
Universal Life for comment on Spitzer`s suit. Our phone calls were not
returned.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may be
posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly Business
Report is not and should not be considered as investment advice.
Copyright (c) 2004 Community Television Foundation of South
Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
11/12/04:
Paxil & Vioxx Have The FDA Under Fire
PAUL KANGAS: New York`s AG also took aim at the Food and Drug Administration
today. Eliot Spitzer blasted the agency, saying it doesn`t make sure the
drug industry discloses negative results about its products. This summer,
Spitzer settled charges against GlaxoSmithKline on allegations the company
kept negative data about its antidepressant Paxil from the public. But
concerns about the FDA`s handling of both Paxil and Merck`s Vioxx have the
agency under fire. Stephanie Woods reports.
STEPHANIE WOODS, NIGHTLY BUSINESS REPORT CORRESPONDENT: The Food and Drug
Administration is in the midst of digging itself out of a controversy over
its drug approval process. At a ground breaking ceremony this week for a
new building that will house the agency`s drug evaluation and research
center, Acting Commissioner Lester Crawford admitted his agency isn`t
perfect when it comes to keeping drugs with dangerous side effects off the
market.
LESTER CRAWFORD, ACTING COMMISSIONER, FDA: It is a fact that the American
people need to come to grips with that between 2 percent and 3 percent of
all the drugs that go on the market, have to come off the market at some
point. We need to improve on that. That`s been true since 1975 and we`re
not making any progress with it.
WOODS: The FDA says it is working to improve the drug safety review
process. It has contracted with the Institute of Medicine to review the
FDA`s procedures. The agency also promises to be more vigilant about
listening to doctors who see dangerous drug side effects and it`s
conducting a nationwide search for a director to head its office of drug
safety. Critics say these steps are little more than cosmetic and don`t
address a fundamental problem at the FDA.
DR. SIDNEY WOLFE, DIR., PUBLIC CITIZEN`S HEALTH RESEARCH GROUP: The FDA is
much more concerned about pleasing the industry from which it is getting an
increasing portion of its funds, than it is in acting as a part of the
public health service, which the FDA technically is.
WOODS: Lawmakers are now investigating how the agency handled Merck`s
pulling Vioxx off the market and whether the FDA ignored its own scientists
when they found problems with the drug. The Senate Finance Committee has
called the FDA and Merck to testify next week. Reform advocates say
changes need to be made in how drugs are approved before they get on the
market.
WOLFE: FDA is handicapped by their inability to require companies to show
that a new drug is safer and/or more effective than an older drug and the
last thing in the world the pharmaceutical industry will allow is
legislation that would give FDA this authority. There are more
pharmaceutical industry lobbyists in Washington than there are members of
Congress.
WOODS: Drug companies say they do demonstrate a drug`s unique benefits
during the FDA approval process and they say the agency has all the power
it needs.
HENRY MCKINNELL, CHAIRMAN & CEO, PFIZER: The FDA has always been very
aggressive in ensuring safety in the drug supply in America. They look at
all the data that`s available, all the studies that have been done, all the
adverse event reports that are filed and make a judgment in the labeling of
the drug, how they think it should be used effectively and safely.
WOODS: The FDA says wholesale changes in the approval and review process of
drugs could have dangerous side effects of their own.
CRAWFORD: These drugs when they go on the market, including Vioxx, save
thousands of lives and make people`s life more bearable, so we can`t just
say we`re not going to approve any new drugs. We have to approve them
correctly, using the latest science and we can do better, but it has to be
the industry that helps us do better.
WOODS: And finding that delicate balance among the drug industry, the
agency, and the public good is the critical challenge facing the FDA.
Stephanie Woods, NIGHTLY BUSINESS REPORT, Washington.
To Learn More about this topic, click
here.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may be
posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly Business
Report is not and should not be considered as investment advice.
Copyright (c) 2004 Community Television Foundation of South
Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
11/12/04:
Retail Sales Slow Pre Holiday-Will It Last?
SUSIE GHARIB:After a buying splurge in September, consumers
were a bit more cautious last month. The Commerce Department said today
that retail sales rose 0.2 percent in October, after a 1.6 percent gain in
September. The slowdown came from a big drop in auto sales. When you
factor that out, sales were up 0.9 percent. But economists predict this
trend of not so stellar sales will continue.
DREW MATUS, ECONOMIST, LEHMAN BROTHERS: We don`t look for retail sales to
accelerate from these levels. Most likely they`ll come off of it.
However, you know, we had a 0.9 percent gain in ex auto retail sales this
month. Would we expect it to fall into negative territory? No. But it
should be nice, solid retail sales going forward for the consumer.
GHARIB: As for the upcoming holiday shopping outlook, Matus expects decent
sales but not a blowout season.
KANGAS: But one retailer in New York City had a blow out of a day today.
The Swedish retailer H&M, best known worldwide for hot apparel at cool
prices, was offering a bit of fashion history to American consumers.
Suzanne Pratt explains.
SUZANNE PRATT, NIGHTLY BUSINESS REPORT CORRESPONDENT: At 8:30 this morning,
in a cold and persistent rain, the line was around the block at H&M`s Fifth
Avenue flagship. By 9:00 the real fun began, a lot of grabbing, a little
pushing, but mostly fashion heaven, all for a small piece of Karl
Lagerfeld. Lagerfeld, Chanel`s top designer, is a fashion icon. The mere
fact that he agreed to tailor a bargain line exclusively for H&M speaks
volumes about the Swedish retail giant. H&M says the union is a perfect
fit.
SANNA LINDBERG, PRESIDENT, U.S. OPERATIONS: I think as we are a company we
always want to surprise our customers. We felt this was a good opportunity
as both of us have mutual respect for each other`s job.
PRATT: While the Lagerfeld line is expected to sell out in U.S. stores by
this weekend, it has been tougher than anticipated for H&M to crack the
American market. Even though U.S. sales were up 27 percent in its most
recent quarter, the company has yet to break even here. In just five
years, H&M has ballooned to 75 stores, concentrated mostly in the
northeast. No other European retailer has expanded so quickly on U.S.
soil. But, experts say most Americans are still not familiar with it.
DANA TELSEY, RETAIL ANALYST, BEAR STEARNS: Coming to the United States is
very difficult. Just like any U.S. retailer going overseas, building brand
name awareness is key, especially when you have a competitive environment
like you do in the U.S.
PRATT: And experts say some of those competitors, namely Forever 21, the
Gap and Zara should be taking notice of H&M and its unique brand of
disposable fashion. Not only does it offer the hottest trends at
affordable prices, but H&M`s lead time on garments is an unprecedented
three weeks. That means fast fashion, something relatively new to most
American shoppers.
WALTER LOEB, RETAIL ANALYST, LOEB ASSOCIATES: It is always fresh, new and
exciting in the stores. It does not rely on a continuity of style. It
relies on freshness. There is never the same thing over again.
PRATT: H&M has fairly grand plans for its future here in the U.S. Although
it does not expect to open a store in every state, it is planning for 15 to
20 new stores next year and more after that. Suzanne Pratt, NIGHTLY
BUSINESS REPORT, New York.
Nightly Business Report transcripts are available
on-line post broadcast. The program is transcribed by eMediaMillWorks.
Updates may be posted at a later date. The views of our guests
and commentators are their own and do not necessarily represent
the views of Community Television Foundation of South Florida,
Inc. Nightly Business Report, or WPBT. Information presented
on Nightly Business Report is not and should not be considered
as investment advice. Copyright (c) 2004 Community Television
Foundation of South Florida, Inc. ALL RIGHTS RESERVED. Terms
of use.
11/12/04:
China Gets Competitive As Car Sales Shift Into Slow
SUSIE GHAIRB: China`s economic engine has been moving at full steam
ahead. But it looks like a dip in auto sales there may be signaling a
bigger trend: slowing growth. Cathy Robinson reports from Hong Kong.
CATHY ROBINSON, NIGHTLY BUSINESS REPORT CORRESPONDENT: The domination of
China`s market is every car manufacturer`s dream. Over two million cars
were sold in China last year and analysts are forecasting that number will
jump to 20 million cars by the year 2020. But while China`s auto industry
reported an increase in combined revenues by foreign and domestic firms of
23 percent or $75.6 billion U.S. during the first half of this year, that
figure is more than 2 1/2 percentage points lower than the revenues
recorded in the same period last year. Analysts say Beijing`s decision to
curb spending, including its recent move to hike interest rates for the
first time in nearly a decade, has become an important factor in dragging
down car sales.
CHRISTOPHER LEE, ANALYST, STANDARD & POORS: The macroeconomic timing
measures including credit tightening and that means auto credit financing
has been difficult to come by. Car loan default rates have been going up,
so banks been very cautious about lending.
ROBINSON: Auto industry watchers in China and Hong Kong like Lee say
hardest hit by the spending curbs are China`s mid-sized models.
LEE: The luxury end of the markets, the volume is small and most people
who can afford it usually use cash to buy the cars and then in the lower
end, the affordability is harder because the prices are significantly
more .
ROBINSON: But the government`s ongoing efforts to curb spending are not the
only reason why more people are taking a wait and see attitude to buy a new
set of wheels. Many prospective owners believe deep price cuts are just
around the corner.
LEE: Consumers are looking for prices to come down, because prices have
been coming down since China joined WTO. The tariff`s been coming down and
local manufacturers are slashing prices as a result, so consumers are
looking for prices to go down on a year on year basis because we expect
tariffs to go down some more by 2006.
ROBINSON: Mary Poon of Honda China says this year`s round of competitive
price cutting began at the beginning of the year and intensified about the
same time the government`s spending slowdown was announced.
MARY POON, HONDA MOTORS/CHINA CO. LTD. Every manufacturer increasing
their production capacity and then (INAUDIBLE) expanding their market
share, so that`s why (INAUDIBLE) how to get more (INAUDIBLE) The only way
is they want to cut prices.
ROBINSON: A price war could be good for China`s buyers, since they pay 40
to 50 percent more for a car than their counterparts in the west.
Aggressive price cutting could also result in a shakeout of the motor
vehicle industry. Cathy Robinson, NIGHTLY BUSINESS REPORT, Hong Kong.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may
be posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly
Business Report is not and should not be considered as investment
advice. Copyright (c) 2004 Community Television Foundation
of South Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
11/12/04:
"Market Monitor"-George Muzea, president of Muzea Insider Consulting Services
PAUL KANGAS: My guest "market monitor" this week is George Muzea, president of
Muzea Insider Consulting Services. Welcome back to NIGHTLY BUSINESS REPORT
George.
GEORGE MUZEA, PRESIDENT, MUZEA INSIDER CONSULTING SERVICES: Good to be
here again Paul.
KANGAS: Your specialty is tracking what corporate insiders are doing with
respect to their company stock, buying or selling. Give us an update on
any clear-cut trends going on right now.
MUZEA: Well, insiders are relatively neutral. They`re not selling at record
levels; the selling is quite normal. What`s a little disturbing to me is
lack of insider buying, particularly when we broke the 10,000 area where
they didn`t step up. That suggests to me that this in next couple
quarters, there will be more companies disappointing than Wall Street is
prepared for.
KANGAS: On your last visit with us in early March, you were rather negative
on the market and that was the beginning of a significant downtrend and
that was tipped off to you by lack of insider buys.
MUZEA: That`s right and I thought also at that time we would have a bottom
possibly in the fourth quarter, which is working out too. But yes,
insiders have, are really good clues that tops and bottoms, particularly if
it`s contrary to what the public is doing.
KANGAS: What`s more compelling, a buy by an insider or a sell by an
insider?
MUZEA: I think buying is more important because there`s so many more
reasons why insiders sell. They have a tendency to sell their stocks --
KANGAS: . put their kids through college.
MUZEA: Yes, exactly and if they`re selling small pieces like 10 percent or
less, then it`s actually a positive development. So the only time you
really want to concern yourself with insiders selling after the stock has
rolled over and is sliding down. They should be buying at the price
(INAUDIBLE) so you want to look to divergences (ph).
KANGAS: On that early March visit with us, you had some recommendations for
our viewers. Let`s take a look at how they did. On the buy side, you like
Tyco, which is up 15 percent, because it was insider buying. That was a
good call. That worked out. Are you still with Tyco?
MUZEA: No, we`re neutral now, no insider activity.
KANGAS: And First Niagara Financial didn`t do much of anything in the
period. I think it`s just practically unchanged. Are you still with it?
MUZEA: I still like it, I own it personally in my IRA and it was a recent
insider buy, so I`m still positive about that.
KANGAS: There was one stock that you said short, sell it and that was
Aquantive and that is down over 10 percent. That was a good one.
MUZEA: Yeah, and earlier, later about in August I believe it got down to 7
and we covered it.
KANGAS: You did cover it?
MUZEA: Yes, because insiders turn neutral.
KANGAS: So you`re out of the short.
MUZEA: We`re out of the short position.
KANGAS: How about now? How are things looking?
MUZEA: I don`t own any of the three stocks that I`m going to mention today
on the long side and I`m not short one of the ones we`ll talk about. But
again, I think it`s very important for the public to be very selective on
buying and buy stocks that aren`t hitting new highs and buy the ones that
have been hurt a little bit earlier in the year.
KANGAS: Let`s have a look at your first recommendation.
MUZEA: OK.
KANGAS: ValueVision.
MUZEA: This is a stock that obviously, as you can see is building a base
down here and is insider buying and the smart insider and we like that
pattern.
KANGAS: Right. This is a company involved with TV home shopping among other
things.
MUZEA: Yes. Right.
KANGAS: OK, let`s move along to the second one. There we see HRPT
Properties.
MUZEA: This is a commercial real estate trust company and we like the fact
that the stock was lower and now it`s higher and insiders paid up the
stock.
KANGAS: Boy, it had quite a run up earlier in the year.
MUZEA: A yield of 7 1/2 percent, so the fact that they bought indicates to
me that there`s a good possibility that the dividend`s going to be very
secure.
KANGAS: So good insider buying by people that you consider to be pretty
smart.
MUZEA: Yes.
KANGAS: All right. How about the third one?
MUZEA: The third one is Trimeris, which is a biotech company and this is
another beaten down stock that`s (INAUDIBLE) and we have a smart buyer
picking up some shares. Again, you have to be patient with these types of
stocks, but I think there`s a lot less risk buying a company like this than
something that`s hitting new highs today (INAUDIBLE).
KANGAS: OK, three on the buy side. You don`t own any of them.
MUZEA: No I don`t.
KANGAS: But you follow them pretty closely.
MUZEA: Yes (INAUDIBLE).
KANGAS: How about on the sell side?
MUZEA: On the sell side, I`m a little concerned with the insider trading
pattern in Cott. Again, we don`t follow the fundamentals of the companies;
we just look at insider trading.
KANGAS: You hardly know what they do.
MUZEA: Exactly and it`s not our job to be concerned with it.
KANGAS: This is a beverage company.
MUZEA: This is a beverage company, but I don`t like the fact insiders
sold at 33 and then the stock came down to 24. It`s rallied back to 26 and
they`re selling again. I don`t like that particular pattern.
KANGAS: OK. You had two out of three on the plus side last time, let`s hope
you`re hitting on all four this time.
MUZEA: Thank you.
KANGAS: Pleasure to have you with us. My guest market monitor George Muzea
of Muzea Insider Consulting.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may
be posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly
Business Report is not and should not be considered as investment
advice. Copyright (c) 2004 Community Television Foundation
of South Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
11/12/04:
Paul Kangas' "Stocks In The News"
PAUL KANGAS: Stock prices were mixed early today. Negative factors included
profit taking after yesterday`s rally and disappointing October retail
sales which we`ll detail shortly. Among positive factors, a good gain in
Dell and a better than expected rise in November`s University of Michigan
consumer sentiment index.
At mid session, the Dow was up 25 points; Nasdaq up seven. Strong seasonal
demand for stocks kept the rally going this afternoon so the market ended
near its best levels. The Dow Industrial Average closed up 69.17 at
10,539.01 and this week, the Dow fell twice, rose three times, had a net
gain of 151 1/2 points. The NASDAQ Composite was up 24 points today to
2085.34. It was higher in four out of this week`s five sessions for a net
gain of 46.40 points. The Standard & Poor`s 500 Index climbed 10 2/3 points
to 1184.17 today.
In the bond market, the 10-year note rose 16/32 to par and 18/32 putting
the yield back down to 4.18 percent.
Big board volume leader on 56.6 million shares, NorTel Networks (NT) down
$0.34. That`s a 10 percent drop. The company`s extending the delay of its
financials statements to permit resolution of various accounting matters.
Pfizer (PFE) was up $0.30.
Advanced Micro Devices (AMD) had a very good day, up $2.43. Wells Fargo
Securities began covering the stock with a buy recommendation and a $27 a
share price target.
Lucent Technologies (LU) a $0.07 gain.
Calpine (CPN) was fifth in volume, moving up $0.27 a share.
Agilent Technologies (A) tumbling $3.10. Fourth quarter earnings came in
at $0.30 a share, a penny below the Street estimate and the company sees
first quarter earnings at $0.14 to $0.21. The Street estimate is way up
there at $0.27. Bank America downgraded the stock from "buy" to a "sell."
General Electric (GE) up $0.45.
$0.78 gain in HCA (HCA).
Citigroup (C) $0.81 rise.
And tenth in volume Merck & Company (MRK) gaining $0.30 a share.
Delta Air Lines (DAL), nice percentage move, 8.5 percent with that $0.54
rise. That`s a positive reaction of course to the pilots agreeing to take a
32 1/2 percent wage cut. That`s a savings of $1 billion annually, could
keep the company out of bankruptcy.
Abbott Laboratories (ABT) down $1.12. Smith Barney brokerage began covering
the stock with a "sell" recommendation, traded as low as $43.68 today.
Kohl`s Corporation (KSS), the department store chain, down $1.16. Fourth
quarter earnings $0.42, up from $0.35 last year. That was just in line with
estimates, but sales were below expectations and Prudential downgraded it
from "overweight" to "neutral." Deutsche Bank downgraded it from "buy" to
just a "hold" recommendation.
Payless Shoesource (PSS) up $1.86. Excluding items, the company`s third
quarter earnings $0.17, way up from the Street estimate of a nickel a share
and Standard & Poor`s repeated a "buy" recommendation.
Veritas DGC (VTS) gained $2.64. Jefferies brokerage upgraded it from
"hold" to a "buy" recommendation.
And then AMN Healthcare Services (AHS) up $1.68. Suntrust Robinson Humphrey
brokerage upgraded that stock from "neutral" to a "buy," a lot of "buy"
recommendations today.
Hormel Foods (HRL) did well, up $3.10. Company increased its fourth quarter
earnings estimates from around $0.43 a share to as high as $0.50 a share.
And Corn Products International (CPO) rising $2.19. Smith Barney upgraded
that stock from "hold" to a "buy."
Microsoft (MSFT) topped the active list on NASDAQ, down a penny.
But then Dell (DELL) moving up $3.19. As we reported, after the close
yesterday, company in with record earnings, up 26 percent for the latest
quarter.
Then Google (GOOG) down $1.02 after a good gain yesterday.
Intel (INTC) $0.52 rise.
And the same story for Cisco Systems (CSCO), which was fifth in dollar
volume.
eBay (EBAY) gained $2.05.
Research In Motion (RIMM) down $1.
TASER International (TASR) $0.45 loss.
Yahoo! (YHOO) edged a penny higher.
And Applied Materials (AMAT) a $0.09 gain, tenth in volume on NASDAQ>
Dynamic Materials Corporations (BOOM) up $3.75. Third quarter earnings more
than tripled, $0.22 versus $0.07. The company has a record backlog and it`s
in the exclusive, explosive metalworking business and the trading symbol
incidentally is BOOM, B-O-O-M.
And finally we see Martek Biosciences (MATK), the company had a European
oil blend patent revoked after challenges by two competitors. The company
plans to appeal.
Those are the stocks in the news tonight.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may be
posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly Business
Report is not and should not be considered as investment advice.
Copyright (c) 2004 Community Television Foundation of South
Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
11/12/04:
Market Stats
NET PERCENT
CLOSE CHANGE CHANGE
DOW CLOSE 10539.01 +69.17 + .7
HIGH 10539.60
LOW 10460.40
NASDAQ COMP. 2085.34 +24.07 +1.2
HIGH 2085.34
LOW 2056.41
VOLUME 1,536.0
PREVIOUS 1,397.1
UP VOLUME 1,178.3
DOWN VOLUME 338.3
DOW TRANSPORTS 3628.20 +4.90 + .1
DOW UTILITIES 330.64 +4.57 + 1.4
CLOSING TICK +1450
S&P 500 1184.17 +10.69 + .9
S&P 100 566.22 +6.04 + 1.1
MIDCAP 400 634.28 +7.00 + 1.1
REUTERS/CRB 283.29 -.78 - .3
NYSE COMPOSITE 7014.18 +63.21 + .9
VALUE LINE 386.44 +3.76 + 1.0
RUSSELL 2000 621.98 +5.68 + .9
DJW 5000 11609.67 +105.25 + .9
U.S. TREASURIES
5-YEAR NOTE 3.375%
Oct. 15,2009 99 31/32 +8/32 + 3.51
10-YEAR NOTE 4.25%
Aug. 15,2014 100 18/32 +16/32 + 4.18
30-YEAR NOTE 5.375%
Feb. 15, 2031 107 +1 3/32 + 4.90
LEHMAN BROS.
LONG BOND INDEX 1745.38 +4.60
DOW CLOSE 10539.01 +69.17 + .7
ADVANCES 2477
DECLINES 849
NEW HIGHS 494
NEW LOWS 17
NET PERCENT
NYSE MOST ACTIVES 4PM CLOSE CHANGE CHANGE
NT Nortel Networks 3.03 -.34 -10.1
PFE Pfizer 27.45 +.30 +1.1
AMD Advanced Micro 21.02 +2.43 +13.1
LU Lucent Tech 3.90 +.07 +1.8
CPN Calpine 3.13 +.27 +9.4
A Agilent Tech 22.58 -3.10 -12.1
GE GE 36.25 +.45 +1.3
HCA HCA Inc 39.40 +.78 +2.0
C Citigroup 47.07 +.81 +1.8
MRK Merck & Co 26.45 +.30 +1.2
NASDAQ CLOSE 2085.34 + 24.07 + 1.2
VOLUME 2,015.9
PREVIOUS 1,780.5
ADVANCES 1885
DECLINES 1172
NASDAQ ACTIVES
MSFT Microsoft 29.97 -.01 -.0
DELL Dell Inc 40.44 +3.19 +8.6
GOOG Google 182.00 -1.02 -.6
INTC Intel 23.69 +.52 +2.2
CSCO Cisco Systems 19.26 +.52 +2.8
EBAY eBay 109.89 +2.05 +1.9
RIMM Rsch In Motion 83.00 -1.00 -1.2
TASR Taser Intl 57.50 -.45 -.8
YHOO Yahoo! 37.80 +.01 +.0
AMAT Applied Matl 16.17 +.09 +.6
AMEX CLOSE 1356.24 + 15.31 + 1.1
INDEX SHARES
DIA DIAMONDS TRUST 105.65 +.59 +.6
QQQ NASDAQ 100 38.66 +.39 +1.0
SPY S&P DEP.RECEIPTS 118.79 +.93 +.8
STOCKS IN THE NEWS
DAL Delta Air Lines 6.84 +.54 +8.6
ABT Abbott Labs 44.18 -1.12 -2.5
KSS Kohl's 52.04 -1.16 -2.2
PSS Payless Shoes 12.93 +1.86 +16.8
VTS Veritas DGC 23.14 +2.64 +12.9
AHS AMN Healthcare 15.72 +1.68 +12.0
HRL Hormel Foods 31.87 +3.10 +10.8
CPO Corn Produce 51.93 +2.19 +4.4
BOOM Dynamic Materials 7.41 +3.75 +102.4
MATK Martek Bioscience 43.71 -3.87 -8.1
|
